The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
Open accessAbstract
OBJECTIVES: Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD. METHODS: In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Previous biological DMARD treatment was permitted. Patients received tadekinig alfa 80 mg or 160 mg subcutaneously three times per week for 12 weeks; those receiving 80 mg not achieving early predicted response criteria (reduction of ≥50% CRP values from baseline and fever resolution) were up-titrated to 160 mg for a further 12 weeks. The primary endpoint was the occurrence of adverse events (AEs) throughout the study. RESULTS: Ten patients were assigned to receive 80 mg tadekinig alfa and 13 patients to the 160 mg dose. One hundred and fifty-five treatment-emerging AEs were recorded, and 47 were considered related to the study drug. Most AEs were mild and resolved after drug discontinuation. Three serious AEs occurred, one possibly related to treatment (toxic optic neuropathy). At week 3, 5 of 10 patients receiving 80 mg and 6 of 12 patients receiving 160 mg achieved the predefined response criteria. CONCLUSIONS: Our results indicate that tadekinig alfa appears to have a favourable safety profile and is associated with early signs of efficacy in patients with AOSD. TRIAL REGISTRATION NUMBER: NCT02398435.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for classification of adult Still's disease.
Yamaguchi, M., Ohta, A., Tsunematsu, T., Kasukawa, R., Mizushima, Y., Kashiwagi, H., Kashiwazaki, S., Tanimoto, K., Matsumoto, Y., & Ota, T. (1992) · PubMed · Cited by 1,788
Interleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
Interleukin-18 Binding Protein
Novick, D., Kim, S.-H., Fantuzzi, G., Reznikov, L. L., Dinarello, C. A., & Rubinstein, M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80013-8 · Cited by 779
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
De Benedetti, F., Brunner, H. I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., Cuttica, R., Ravelli, A., Schneider, R., Woo, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112802 · Cited by 763
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., & Sève, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.058 · Cited by 518
Kawashima, M., Yamamura, M., Taniai, M., Yamauchi, H., Tanimoto, T., Kurimoto, M., Miyawaki, S., Amano, T., Takeuchi, T., & Makino, H. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<550::aid-anr103>3.0.co;2-5 · Cited by 268
Adult-Onset Still Disease: Manifestations, Treatment, Outcome, and Prognostic Factors in 57 Patients
Gerfaud-Valentin, M., Maucort-Boulch, D., Hot, A., Iwaz, J., Ninet, J., Durieu, I., Broussolle, C., & Sève, P. (2014) · Medicine · doi:10.1097/md.0000000000000021 · Cited by 243
Woo, P., & Wedderburn, L. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60640-x · Cited by 170
Elevated serum levels of free interleukin-18 in adult-onset Still’s disease
Girard, C., Rech, J., Brown, M., Allali, D., Roux-Lombard, P., Spertini, F., Schiffrin, E. J., Schett, G., Manger, B., Bas, S., et al. (2016) · Rheumatology · doi:10.1093/rheumatology/kew300 · Cited by 166
Self-citation
Cited by
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Interleukin-18 in Health and Disease
Yasuda, K., Nakanishi, K., & Tsutsui, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030649 · Cited by 563
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T.-D. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 438
A comprehensive review on adult onset Still's disease
Giacomelli, R., Ruscitti, P., & Shoenfeld, Y. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.07.018 · Cited by 419
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Metadata
- Authors
- Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Kötter, I., Hachulla, E., Morel, J., Schaeverbeke, T., Hamidou, M. A., Martin, T., Hellmich, B., Lamprecht, P., Schulze-Koops, H., Courvoisier, D. S., Sleight, A., & Schiffrin, E. J.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 77
- Issue
- 6
- Pages
- 840-847
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2788608061
- Cited by
- 291
- References
- 17
- FWCI
- 20.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. https://app.cochat.ai/papers/10.1136/annrheumdis-2017-212608
- The paper
- Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Kötter, I., Hachulla, E., Morel, J., Schaeverbeke, T., Hamidou, M. A., Martin, T., Hellmich, B., Lamprecht, P., Schulze-Koops, H., Courvoisier, D. S., Sleight, A., & Schiffrin, E. J. (2018). Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-212608
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.